

RESEARCH

Open Access

A network model of genomic hormone interactions underlying dementia and its translational validation through serendipitous off-target effect

Erfan Younesi^{1,2*} and Martin Hofmann-Apitius^{1,2}

Abstract

Background: While the majority of studies have focused on the association between sex hormones and dementia, emerging evidence supports the role of other hormone signals in increasing dementia risk. However, due to the lack of an integrated view on mechanistic interactions of hormone signaling pathways associated with dementia, molecular mechanisms through which hormones contribute to the increased risk of dementia has remained unclear and capacity of translating hormone signals to potential therapeutic and diagnostic applications in relation to dementia has been undervalued.

Methods: Using an integrative knowledge- and data-driven approach, a global hormone interaction network in the context of dementia was constructed, which was further filtered down to a model of convergent hormone signaling pathways. This model was evaluated for its biological and clinical relevance through pathway recovery test, evidence-based analysis, and biomarker-guided analysis. Translational validation of the model was performed using the proposed novel mechanism discovery approach based on 'serendipitous off-target effects'.

Results: Our results reveal the existence of a well-connected hormone interaction network underlying dementia. Seven hormone signaling pathways converge at the core of the hormone interaction network, which are shown to be mechanistically linked to the risk of dementia. Amongst these pathways, estrogen signaling pathway takes the major part in the model and insulin signaling pathway is analyzed for its association to learning and memory functions. Validation of the model through serendipitous off-target effects suggests that hormone signaling pathways substantially contribute to the pathogenesis of dementia.

Conclusions: The integrated network model of hormone interactions underlying dementia may serve as an initial translational platform for identifying potential therapeutic targets and candidate biomarkers for dementia-spectrum disorders such as Alzheimer's disease.

Keywords: Hormone, Dementia, Network model, Translational validation, Off-target effect

* Correspondence: erfan.younesi@scai.fraunhofer.de

¹Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Schloss Birlinghoven, 53754, Sankt Augustin, Germany

²Bonn-Aachen International Center for Information Technology, University of Bonn, Bonn, Germany

Background

The clinical hallmark of dementia-spectrum diseases including Alzheimer's disease (AD) and front temporal dementia is the gradual memory loss and impairment of other cognitive functions, which has been attributed to the aggregation of amyloid fibrils, a process known as amyloidogenesis [1-3]. However, recent findings indicate that many peptide and protein hormones are stored in secretory granules in the form of functional amyloid fibrils and such an amyloid-like structure is necessary for their natural functioning as hormones [4].

Moreover, observational studies on the beneficial effect of estrogen-based hormone therapy on cognitive impairment have also reported conflicting results [5]. Indeed, gender-specific risk profiles observed for dementia in elderly men and women have drawn attention to the impact that sex hormones, as risk factors, may have on progression from mild cognitive impairment (MCI) to dementia [6,7]. The higher risk of AD and dementia incidence in women has been linked to high serum levels of endogenous estrogen [8] and it has been shown to be influenced by hormone replacement therapy [9-13], although a better cognitive performance after current hormone therapy was dependent on the duration and type of treatment [14].

On the other hand, both basic and clinical research findings have consistently shown influence of a range of hormones on some cognitive functions in AD. For example, high levels of leptin in blood have been associated to a lower risk of AD [15] and leptin replacement therapy has been suggested as a novel therapeutic strategy for AD [16]. The loss of melatonin in cerebrospinal fluid has been observed in patients with dementia of Alzheimer's suggesting that it may play a role in the pathogenesis of AD [17-20]. A low thyroid hormone level has been also associated with AD [21,22]; the administration of thyroid hormone in AD model mice prevented cognitive deficit and improved the neurological function [23]. In Alzheimer's disease, a greater cognitive impairment has been found to be associated with lower CSF concentrations of corticotropin-releasing hormone [24,25]. There is evidence that growth hormone (GH) declines with advancing age or in Alzheimer's disease [26-28] and that daily treatment of healthy older adults with GH improves the cognition independent of gender [29]. A recent study also shows that GH can boost memory retention in rats [30].

There are several lines of evidence that point to the role of insulin signaling in AD; e.g. insulin levels in the CSF of AD patients is lower than healthy controls [31,32], insulin receptor signaling is compromised in AD neurons [33], and insulin resistance is associated with reductions in cerebral glucose metabolic rate, which is a risk factor for developing AD dementia [34]. Interestingly, epidemiological findings indicate that type II diabetes mellitus is linked to developing and exacerbating AD

pathology [35,36] so that Alzheimer's has been even proposed by some authors to be 'type III diabetes' [37,38]. Similar neuroendocrine disturbances have been reported for Huntington's disease under which the thyrotropic, somatotropic and gonadotropic axes are altered [39].

All the above-mentioned evidence, including inconsistent results and disparate findings, suggests that there is a gap between the knowledge obtained from basic research and findings of clinical investigations on the association between hormones and cognition. Context-specific networks of molecular interactions provide a relevant framework for supporting translation of basic knowledge into clinically relevant information through integrative modeling of disease mechanism. Current Alzheimer's disease maps, including the recent Alz Pathway model [40], lack the focused representation of hormone signaling pathways. Therefore, this work describes the first attempt to characterize the hormone/hormone-receptor interactions relevant to dementia disorders under a unified framework of the interconnected hormonal components.

Methods

Figure 1 summarizes the overall strategy used for this study. It demonstrates a top-down integrative (knowledge- and data-driven) approach to modeling hormone protein interaction network.

Literature mining

Our retrieval system was composed of two software components: the dictionary-based text-mining tool, ProMiner




Figure 1 Schematic representation of the methodology used for construction and analysis of dementia-related hormonal network.

[41], and the semantic search engine, SCAIView [42]. The ProMiner software uses dictionaries for the recognition of a variety of different terminologies including gene, protein, disease, SNP, drug, etc. The SCAIView software deploys the results from ProMiner annotations, ranks the extracted genes/proteins based on relative entropy scoring function (i.e. mutual information measure), and displays the named entities by tagging them through the text. SCAIView academic version can be freely accessed at <http://bishop.scai.fraunhofer.de/scaiview/>. PubMed abstracts were searched for all instances of genes and proteins, which are mentioned in the context of 'dementia' as keyword (accessed as of 08.02.2011). The retrieved entities were manually checked for their true relevance to both hormones and dementia in the context of their abstracts.

Network reconstruction and annotation

The results from text-mining were cross-checked with the contents of the EndoNet database [43] and the confirmed entities were used as seed proteins in the BIANA tool for reconstruction of the dementia-related hormonal network (DHN) at level 2 [44]. The initial protein-protein interaction network was constructed around the seed set. In order to reduce the dimensionality and increase the confidence, interactions that are only supported by the yeast two-hybrid method were removed and those interactions that are independently confirmed by two or more experimental methods were maintained. The network was visualized and statistically analyzed in the Cytoscape and Gephi environments [45,46]. G-lay clustering algorithm was used for modularity analysis [47].

Pathways used for the recovery test

For the pathway recovery test, we obtained the following expert-curated hormonal pathways, used them as gold standard, and mapped them onto the network: growth hormone pathway [48], insulin signaling pathway [48], leptin signaling pathway [49], thyroid hormone signaling [50], regulation of the estrogen receptor pathway [48], corticotropin-releasing hormone pathway [51], and Melatonin signaling pathway [52].

Statistical analysis

Gene set enrichment analysis was performed using the Molecular Signature Database [53]. DAVID functional annotation tool was used for annotation of differentially expressed genes in the network [54].

Translational validation

For establishing the clinical relevance of the core DHN model, knockout mouse phenotypes were retrieved from MGI database [55]. For retrieval and extraction of putative biomarker information from the literature, biomarker terminology was used [56]. Pathway membership

for each target was obtained from KEGG database [57] and their association to disease was determined using genetic association database [58]. Information on brain tissue specificity of the targets was obtained from Tissue Distribution Database [59] but the higher resolution information at the cell type level was retrieved from the literature using SCAIView search engine.

DrugBank was searched for the proteins of the core DHN as targets of approved drugs [60]. Then PubMed was searched for supporting evidence of positive off-target effects of non-dementia drugs that showed potential implication of those drug-targets in improvement of dementia.

Results

Enrichment of dementia-related proteins for hormone signaling activity

Mining the knowledge space of the literature for proteins that are shown to play a role in dementia resulted in a list of 1960 entities, which were ranked based on their mutual information (see Methods). Due to the fact that high-dimensional information returned by retrieval systems inherits noise, the next step was to observe whether signals of hormonal proteins could be detected in this large list of entities. The gene set enrichment analysis (GSEA) of these proteins revealed under-represented signatures of hormone activities in pathway analysis as well as implicit but statistically significant presence of hormone-related regulatory gene sets in GO biological process annotations (Additional files 1 and 2, respectively). However, at the level of GO molecular function, these signatures showed significant over-representation for hormone activity, neuropeptide hormones and hormone signaling pathways (Table 1).

The results of this observation led us to raise the hypothesis that an endocrine interaction network may exist that substantially contributes to the pathology of the dementia-spectrum diseases. To investigate this hypothesis, we used text-mining and knowledge discovery technologies to narrow down our search for retrieval and extraction of instances of hormone proteins and their receptors, which are cited in the literature (Medline abstracts) in relation to dementia. The focused search resulted in retrieval of 1329 documents and 453 protein entities extracted from them. Finally, 89 hormone/hormone-receptor entities were confirmed to play a role as hormone/hormone-receptor after crosschecking the retrieved entities with the contents of the EndoNet database as gold standard (see Methods). We use this initial set of proteins (seed set) as *prior knowledge* to build upon our integrative model.

Dementia-related hormone network (DHN) and its biological relevance

The initial protein-protein interaction network comprises of 6966 nodes (proteins) and 85997 edges (interactions)

Table 1 Analysis of the retrieved data based on enrichment for gene ontology, category of molecular function

Gene set name	Description of annotation	P-value
Amine receptor activity	GO:0008227: Combining with a biogenic amine to initiate a change in cell activity.	3.61E-05
Hormone activity	GO:0005179: The action characteristic of a hormone, any substance formed in very small amounts in one specialized organ or group of cells and carried (sometimes in the bloodstream) to another organ or group of cells in the same organism, upon which it has a specific regulatory action.	1.46E-04
Copper ion binding	GO:0005507: Interacting selectively with copper (Cu) ions.	3.40E-03
Neuropeptide hormone activity	GO:0005184: The action characteristic of a neuropeptide hormone, any peptide hormone that acts in the central nervous system. A neuropeptide is any of several types of molecules found in brain tissue, composed of short chains of amino acids.	6.55E-03
Serotonin receptor activity	GO:0004993: Combining with the biogenic amine serotonin, a neurotransmitter and hormone found in vertebrates, invertebrates and plants, to initiate a change in cell activity.	1.40E-02

but after filtering the number of edges in DHN decreased to 83998. 6515 nodes form a giant connected component and the rest of 451 nodes are singletons without any connection; thus, for simplicity, we only consider the giant component for further analyses. Statistical analysis of the giant component of DHN shows that its node degree distribution could be fitted in the power law of the form $y = 1092.8 \times x^{-1.17}$ with an acceptable goodness of fit (R-squared value = 0.856, Correlation = 0.996). This indicates that the network is of biological nature [61].

The network clustering coefficient of 0.315 and immense distribution of the clustering coefficients around the nodes with more than 100 neighbours is suggestive of a modular organization consisting of several interconnected functional modules. The modularity analysis of the network

revealed four major modules whose functional annotation using GSEA supports the notion of modular organization underlying the network (Figure 2): the largest module with 2037 nodes (Figure 2A) is significantly enriched for regulation of transcription, the second module with 1540 interconnected proteins (Figure 2B) is significantly involved in hormone and receptor signaling, the third module with 1420 proteins (Figure 2C) is significantly annotated for GPCR signaling, and finally the fourth module containing 1312 nodes (Figure 2D) is enriched for protein translation and induction of apoptosis (Additional files 3 and 4). These findings are consistent with the fact that hormone peptides are major ligands for GPCRs and through cellular signaling cascades, they regulate the transcription of target genes in the nucleus.




Figure 2 An overview of modules detected in DHN. 19 modules were detected in DHN out of which 4 modules represent ca. 97% of the network. (A) The largest module is enriched for regulation of transcription. (B) The second module with 1540 interconnected proteins representing hormone and hormone receptor signaling pathways. (C) The third module with 1420 proteins enriched for GPCR signaling. (D) The fourth module containing 1312 nodes is enriched for protein translation and induction of apoptosis.

Evaluation of DHN by pathway recovery

Both the biological relevance and the modularity were further evaluated by mapping the Alzheimer's disease pathway from the KEGG database as well as hormone signaling pathways from other resources (see Methods). Mapping the Alzheimer's disease pathway onto the network resulted in the recovery of all the proteins and their corresponding interactions in the pathway except for APH1A.

Regarding hormone signaling pathways, the number of proteins involved in the actual signaling and the number of mapped proteins for each signaling pathway is shown in Table 2. For two pathways with 100% node recovery, i.e. insulin signaling pathway and growth hormone pathway, manual extraction of edges (interactions) from BioCarta and mapping them onto the network yielded 76% edge recovery (16 out of 21) for the growth hormone pathway and 90% edge recovery (19 out of 21) for the insulin signaling pathway.

We also surveyed our network for the presence of hormone receptors by comparing them to known hormone receptors of genomic neuroendocrine hormones and were able to identify them for majority of these hormones (Additional file 5).

Hormonal convergence in DHN

After the completion of this individual pathway recovery test, we aggregated all the elements of these seven pathways and mapped them onto the giant component of DHN. The aim was to detect the core of DHN where the majority of hormone cross talks occur. A subnetwork of 73 nodes and 133 edges was formed, representing the converged hormonal pathway interactions. Interestingly, 62 of these hormone peptides (ca. 86%) are densely interconnected and form the core of DHN. Besides, their interactions appeared to occur in different regions of the normal brain after adding the context of brain region annotations to each edge using the work of Bossi and Lehner (2009) (Figure 3) [62]. Analysis of these annotations shows

that the majority of the hormonal interactions occur in prefrontal cortex (ca. 93%), hypothalamus (ca. 92%) and cingulate cortex (ca. 90%), respectively (Additional file 6). The finding that interactions of the converged network mostly occur in prefrontal cortex and cingulate cortex is consistent with the neuroanatomical distribution of neurofibrillary tangles and plaques in the cerebral cortex of AD patients [63]. Moreover, the relevance of this finding to clinical attributes of the advanced AD pathology has been shown in several studies (**Prefrontal cortex**: [64,65]; **Cingulate cortex**: [66]; **Hypothalamus**: [67,68]). For example, it has been shown that prefrontal cortex, an important component for working memory, is the site of hormonal effects on cognition including estrogen [69], insulin [70], growth hormone [71], and thyroid hormone [72]. Thus, collective dysregulation of these pathways in prefrontal cortex of AD patients can lead to worsened memory impairment.


As the pathway-wise color codings in the converged hormonal network in Figure 3 indicates, a strong convergence and close interplay of hormone signals can be observed at the molecular level of the brain interactome. The yellow nodes show the common membership of proteins in two or more of these pathways and are significantly enriched for Neurotrophin/Trk signaling (GSEA p-value: $0e^0$, 14 genes in overlap), through which a variety of signaling cascades are connected and signals of neuronal development, survival as well as additional higher-order signals such as learning and memory are transmitted. The extended portion of estrogen signaling pathway in the core interactome is also noted.

Linking hormone-dementia hypothesis to mechanistic evidence

Apart from above *in silico* analyses, we provide more solid support for the hormone-dementia hypothesis from Alzheimer's reference expression data set [73], which has been processed and used for identification of a perturbed protein hub network in Alzheimer's disease by Liang et al. (2012) [74]. The Alzheimer's reference data set provides carefully phenotyped expression data set for six brain regions from late-onset AD patients (GSE5281) and lends support to the hypothesis that most of the differentially expressed genes in these six brain regions represent hub proteins in the hub network specific to Alzheimer's disease. We compared the core DHN with the Alzheimer's hub network derived from Alzheimer's reference expression data set and found 18 hormone signaling proteins in the core DHN that overlap with the hub genes differentially expressed in the hub network of Alzheimer's disease (Additional file 7). As Additional file 7 indicates, all hormone signaling pathways are perturbed in different brain regions, with the largest overlap between insulin and growth hormone signaling pathways. Among

Table 2 List of dementia-related hormone signaling pathways that were recovered fully or partially in DHN

Hormone signaling pathway	No. of proteins in the gold-standard pathway	No. of proteins present in the hormone-dementia network
Estrogen receptor pathway	30	25 (83% recovery)
Insulin signaling pathway	21	21 (100% recovery)
Growth hormone pathway	27	27 (100% recovery)
Leptin signaling pathway	21	17 (80% recovery)
Thyroid signaling pathway	11	8 (72% recovery)
Melatonin signaling pathway	16	16 (100% recovery)
Corticotropin-releasing hormone signaling pathway	17	16 (94% recovery)



these proteins, ESR1 and IRS1 exclusively represent two hormone signaling pathways, namely estrogen signaling pathway and insulin signaling pathway.

Translational validation of the core DHN

To our knowledge, except for hormone therapy with estrogen, there is no clinical trial describing the effect of other hormones on cognition improvement. Hence, in the absence of clinical trials, we propose a strategy for translational validation of the core DHN by showing the clinical relevance of the core DHN to dementia in the first step and then linking molecular signatures - through mouse model phenotypes - to their corresponding clinical manifestations.

The clinical relevance of the core DHN to dementia can be established through biomarker-guided analysis, in

which information of putative molecular indicators of dementia is retrieved and extracted from the literature and further become enriched with pathway membership, disease association and tissue/cell type specificity data (Table 3). Of the proteins in the core DHN, four were found in the literature to be reported as potential biomarkers that show measurable activity under Alzheimer's condition. These four proteins represent four different hormonal signaling pathways, namely growth hormone pathway (MAPK3), corticotropin-releasing hormone pathway (NOS1), melatonin signaling pathway (CREB1) and insulin pathway (JUN), whose measurable activities under AD condition suggest their mechanistic involvement in the pathology of AD dementia.

Next, we sought to investigate the translational value of DHN by linking hormone proteins in DHN

Table 3 Clinical relevance of the core DHN to dementia through biomarker-guided analysis

Target candidate	Pathway membership	Disease association	Biomarker type	Brain tissue specificity	Cell-type specificity
MAPK3	Alzheimer's disease, Prion disease, Type II diabetes mellitus, Insulin signaling pathway, Long-term potentiation	Autism	CSF increased levels AD (PMID: 22145083, 19625747), Phosphorylation (PMID: 19233276, 16920298, 17612901), Alterations in lymphoblasts of AD patients (PMID: 19158936)	Left ventricle, Right ventricle, Brain stem	Microglia, Astrocytes, Neurons
NOS1	Alzheimer's disease, Long-term depression, Calcium signaling pathway	Parkinson's disease, Alzheimer's disease, Diabetes Mellitus type II	Nitric oxide overproduction (PMID: 20804853), nNOS signaling initiated in interneurons (PMID: 16758165), Increased expression of nNOS isoforms in astrocytes (PMID: 12384247)	Substantia nigra, Forebrain, cerebral white matter, Limbic system	Astrocytes, Neurons
CREB1	Huntington's disease, Cholinergic synapse	Alzheimer's disease	Impaired CREB phosphorylation (PMID:22119240)	Substantia nigra, Brain stem, Sub-commissural organ, Brain ventricle, Cerebral gray matter, Cerebral white matter, Forebrain, limbic system	Hippocampal neurons, Dentate gyrus
JUN	GnRH signaling pathway, Neurotrophin signaling pathway, MAPK signaling pathway	Cognitive performance	Prolonged expression of c-Jun (PMID:8774439), Increased immuno-reactivity (PMID:8313943)	Sub-commissural organ, Brain ventricle, Cerebral gray and white matter	Neurons, Microglia, Substantia nigra

to their corresponding knockout mouse phenotypes. Table 4 summarizes 19 knockout mouse models representing 6 hormonal signaling pathways with phenotypes related to the nervous system. It also includes the ratio of knockout studies reporting an effect on the nervous system to studies reporting no effect on the nervous system.

To establish the bridge between the observed mouse phenotypes and the clinical disease manifestation in human, we propose the novel concept of “mechanism discovery through serendipitous off-target effects” based on the secondary positive effect of approved drugs that leads to unexpected and serendipitous clinical observations. Many approved drugs that are routinely used for treatment of human diseases lead to manifestation of so-called ‘hidden phenotypes’ due to binding to unknown targets [75]. The revelation of hidden phenotypes points to the fact that off-target effects sometimes result in positive effects through novel mechanisms of action. The most prominent example is the positive effect of Sildenafil on erectile dysfunction while the drug had been originally developed against angina.

Here we have collected a number of drugs with reported serendipitous effects on cognition that target several proteins in the core DHN (Table 5). Interestingly, all the off-targets of these drugs, when compared to the knockouts in Table 4, correspond to a nervous system phenotype in mice. Landscape illustration of the off-target effects in the core DHN model in Figure 4 shows that modulation of the estrogen signaling pathway by four drugs was more likely to lead to the serendipitous off-target effect on dementia and consequently, to improved cognitive functions observed in patients treated with these drugs.

To enlighten the usability of the DHN model, we performed a more general analysis by systematically searching for non-dementia drugs with targets of the core DHN model and retrieving published studies that support the positive, negative or neutral effect of those drugs on cognition or memory or learning. This analysis demonstrated that of 62 proteins in the core DHN model, 21 (ca. 33%) have been already targeted by at least one drug out of which 18 drugs targeting 13 proteins have shown positive effect, 3 drugs targeting 1 protein have demonstrated negative effect, and 39 drugs targeting 18 proteins have not been investigated in relation to cognitive functions or have not been reported in the literature to have any observed effect on dementia. 21 proteins (ca. 33%) have been targeted by experimental compounds and 20 proteins (ca. 32%) have not been targeted by any drug or compound (Additional file 8). These findings imply that hormone signaling pathways present a promising target space for drug discovery.

Discussion

Integrative modeling approaches provide a suitable medium for fusion of complementary data derived from literature and experiments. Given the fact that molecular mechanism of disease risk factors is often unclear and the exact mode of action of most approved drugs is unknown in most cases, such models can be used to interpret disease mechanism and to predict drug mode of action. In particular, an integrative model allows for inference of cross talks among components of the system, guidance of analysis to the core pathological pathways, and generation of further hypotheses on how risk factors or disease-modifying treatments at molecular level lead to manifestation of positive or negative clinical effects. Accordingly, our *in silico* approach to modeling hormone signaling pathways that underlie dementia pathology provided several novel insights beyond what is already known about hormone signaling pathways in dementia, as follows.

The growing number of findings on the role of hormone signaling pathways in regulation of cognition and memory raises an immediate question: how these bits and pieces of accumulating knowledge are being used to explain the contribution of hormones to improvement or exacerbation of dementia? The dementia-related hormonal network, presented in this paper, provided a first unified picture of the hormonal component underlying cognitive impairment. Convergence of genomic hormonal pathways in the DHN model uncovered tight molecular interconnections and cross talks among hormone signaling pathways and regulatory pathways of neural growth, survival and differentiation. For instance, the observed convergence of estrogen and neurotrophin signaling pathways at the core of DHN has been shown to regulate an array of cytoskeletal and growth-associated genes in cerebral cortex, including tau microtubule associated protein, MAPT [76]. The implication of such hormone signals in the pathology of dementia is supported by the evidence that phosphorylation of MAPT, which leads to neurofibrillary tangle formation and ultimately neurodegeneration, is regulated by the signaling effects of insulin and estradiol [77,78]. Similarly, the regulatory influence of thyroid hormone, melatonin, and corticotropin-releasing factors on hippocampal tau phosphorylation has been documented in the literature [79-81].

The DHN model could guide the mechanism discovery analysis to those signaling pathways that constitute the core pathological processes. The modularity detected in the network implies that hormone receptors and hormone signals in concert with transcription factors may play a significant part in the disease mechanism. The molecular interconnection of insulin pathway to dementia pathology - revealed by the DHN model- may provide a mechanistic explanation for the previous epidemiological

Table 4 Knockout mouse phenotypes observed for several proteins in the core DHN model

Name	Mutation category	Observed effects on the nervous system	Ratio of KO studies with CNS phenotypes to studies without CNS phenotypes
Estrogen signaling			
Esr1 ^{tm1Ksk}	Targeted (knock-out)	abnormal pituitary gland physiology abnormal hypothalamus morphology abnormal innervation	4:8 (50%)
Ncor2 ^{tm1Kjep}	Targeted (knock-out)	abnormal cerebral cortex morphology abnormal neuron differentiation	1:0 (100%)
Hdac2 ^{tm1.2Rdp}	Targeted (knock-out)	abnormal hippocampus CA1 region morphology abnormal dentate gyrus morphology abnormal hippocampus pyramidal cell morphology enhanced long term potentiation	1:3 (34%)
Ccnd1 ^{tm1Wbg}	Targeted (knock-out)	absent Purkinje cell layer abnormal cerebellar granule layer small cerebellum	1:3 (34%)
Crebbp ^{tm1Sis}	Targeted (knock-out)	abnormal forebrain morphology	3:4 (75%)
Insulin signaling			
Jun ^{tm1Wag}	Targeted (knock-out)	abnormal forebrain morphology	1:2 (50%)
Hras1 ^{tm1Grnt}	Targeted (knock-out)	reduced long term potentiation	1:3 (34%)
Csnk2a1	Targeted (knock-out)	abnormal telencephalon development	1:2 (50%)
Mapk3 ^{tm1Gpg}	Targeted (knock-out)	reduced long term potentiation	2:2 (100%)
Leptin signaling pathway			
Lepr ^{tm1.2Chua}	Targeted (knock-out)	abnormal inhibitory postsynaptic currents	1:4 (25%)
Stat3 ^{tm1Aki}	Targeted (knock-out)	abnormal motor neuron morphology abnormal neuron physiology	1:6 (17%)
Hif1a ^{tm1.1Stom}	Targeted (knock-out)	abnormal cerebrum morphology abnormal cerebral cortex morphology loss of cortex neurons abnormal occipital lobe morphology abnormal temporal lobe morphology loss of hippocampal neurons	4:7 (57%)
Thyroid signaling pathway			
Rxrb ^{tm1Rev}	Targeted (knock-out)	abnormal excitatory postsynaptic potential reduced long term potentiation absent long term depression	2:3 (67%)
Corticotropin-releasing pathway			
Gnaq ^{tm1Soff}	Targeted (knock-out)	abnormal glutamate-mediated receptor currents absent long term depression	1:2 (50%)
Bral ^{tm1.1Sva}	Targeted (knock-out)	increased neuron apoptosis abnormal innervation thin cerebral cortex	3:3 (100%)

Table 4 Knockout mouse phenotypes observed for several proteins in the core DHN model (Continued)

Nos1 ^{tm1Pih}	Targeted (knock-out)	abnormal brain wave pattern abnormal long term potentiation reduced long term potentiation absent long term depression decreased synaptic glutamate release abnormal peripheral nervous system regeneration	3:4 (75%)
Melatonin signaling pathway			
Gnai1 ^{tm1Drs}	Targeted (knock-out)	abnormal long term potentiation	1:1 (100%)
Plcb1 ^{tm1Hssh}	Targeted (knock-out)	loss of hippocampal neurons	1:1 (100%)
Creb1 ^{tm1Gsc}	Targeted (knock-out)	abnormal CNS synaptic transmission reduced long term potentiation	1:2 (50%)


studies on the contribution of diabetes mellitus and insulin resistance as risk factors to exacerbation of dementia e.g. [82-84]. For instance, very recently, a 9-year prospective study on 3069 elderly adults without dementia demonstrated that patients who suffered diabetes had significantly worse cognitive decline in comparison with those who did not have the disease, suggesting the contribution of diabetes mellitus severity to accelerated cognitive impairment [85]. An interesting observation in our model is the co-occurrence of diabetes-related proteins in the convergent core of DHN. Indeed, three members of this sub-network (i.e. MAPK1, INSR, SOCS3) belong to the Type II diabetes mellitus pathway, which fall into the bigger insulin

signaling pathway together with SHC1 and ELK1 (Figure 3). As was shown by pathway recovery analysis in Table 2, the insulin signaling pathway is present in the network with the highest number of nodes and edges amongst other signaling pathways. The presence of MAPK1/ELK1/CREBBP axis in the core subnetwork (see Figure 3) and its direct crosstalk to the insulin pathway is consistent with experimental observations that link insulin signaling and diabetes risk to the regulation of learning and formation of long-term memory [86-88].

We showed that the DHN model could have more valuable implications beyond a sole portrait of networked signaling pathways by enabling high-resolution analysis

Table 5 Drugs with serendipitous off-target effects on cognition and memory

Drug name	Main indication	Positive side effect on cognition and memory	Study subjects/design	Supporting evidence (PMID)	Target protein in core DHN
Bexarotene (Targretin)	Skin cancer	Rapid reversal of cognition, social and olfactory deficits	Mouse model of AD	22323736	RXRA RXRB
Tamoxifen	Breast cancer	Higher level of independence in activities of daily life and decision making; relationship of tamoxifen with a lower prevalence of AD	Cross-sectional study of women receiving tamoxifen	11005221	ESR1
Raloxifene	Breast cancer	Reduced risk of cognitive impairment in postmenopausal women	The Multiple Outcomes of Raloxifene Evaluation (MORE) randomized, placebo-controlled trial among postmenopausal women with osteoporosis	15800139	ESR1
Vorinostat	Cutaneous T cell lymphoma (skin cancer)	Complete restoration of contextual memory	Mutant APP ^{swe} /PS1 ^{dE9} mice	20010553	HDAC2 HDAC3
Lovastatin	Hyperlipidemia	Reduction of Abeta formation and slowing the progression of AD	Double-blind randomized study on human subjects	11900994	HDAC2
Resveratrol	Aging	Promoting clearance of Abeta peptides	Various cell lines	16162502	CSNK2A1
Sorafenib	Renal cell carcinoma	Reversal of memory impairment	Transgenic APP ^{swe} mouse model	20201822	BRAF
Naloxone	Opioid overdose	Improvement of learning and memory through enhancement of long-term potentiation	Aged rats with declined memory	14670637 15805661	CREB1



of core molecular events. This was achieved through enhancement of the DHN model with knockout phenotype data and drug-target information. Genetically engineered mouse models play an instrumental role in studying disease mechanism and translating preclinical studies to the clinic [89]. Thus, the knockout phenotypes are good candidates for establishing the link between the molecular mechanism and the disease clinical manifestation. One clear observation from knockout phenotypes in Table 4 is the prominent involvement of all hormone signaling pathways in long term potentiation (LTP) beside other biological processes. It is well known that long term potentiation of synaptic transmission substantially contributes to memory formation [90] and that LTP inhibitors also block memory and learning [91]. Hence, it can be inferred from the model that probably perturbation in hormone signaling pathways may affect LTP adversely. Interestingly, knockout models of three putative biomarkers for dementia in Table 3, namely MAPK3, NOS1 and CREB1, show reduced LTP (see Table 4), which supports the notion that hormone signaling pathways are part of the dementia pathology. It should be noted that these proteins generally exert multiple functions in the biology of nervous system by participating in different signaling pathways and thus, the core DHN model describes their contribution to the hormone-mediated signaling in the context of dementia.

Since mouse knockout phenotypes alone might not be sufficient to concretely conclude about the translational value of our DHN model, introduction of the “serendipitous off-target effect” for linking DHN model to disease mechanism demonstrated to provide further validation for the DHN model. It was shown that inhibition of off-targets belonging to hormone signaling pathways could lead to improvement of memory and learning in human or animal models. Therefore, the enhanced DHN model can be used to predict novel targets out of off-targets or to identify disease-modifying targets and pathways that partially regulate the pathology of disease. For example, HDAC2 knockout mouse models show enhanced LTP, which may indicate HDAC2 might be a potential therapeutic target; on the other hand, the clinical evidence is provided by the off-target effect of Lovastatin on HDAC2: originally designed against hypercholesterolemia, Lovastatin was tested during a double-blind, randomized clinical study on human subjects for its effect on progression of Alzheimer’s disease through reduction of amyloid-beta formation [92]. The study found that Lovastatin decreases the risk of AD progression. Such an inference exemplifies how the novel knowledge on the mechanism of drug effect on disease-related risk factors can be derived from the enhanced integrative model of DHN.

Although DHN provides a unified integrative map of possible hormone signaling mechanism in the context of

dementia, it has its limitations. The inherent issue of network biology is that completeness of molecular network maps is limited to data availability and validity. The DHN model analyzed in this work may not cover all the hormone pathways involved in the pathogenesis of dementia but rather it focuses on the convergent hormone action by the most prominent ones. Furthermore, such models provide only a static picture and do not capture the dynamic behaviour of the system. However, context-specific modeling, as the first step, makes it possible to simulate disease-specific perturbations after incorporation of quantitative data from high-throughput technologies. Such an integrative modeling approach may prove valuable for prediction of potential biomarkers due to the fact that hormones are able to cross the blood-brain barrier by transmembrane diffusion or using transporters and their brain levels reflect blood levels [93]. We plan to keep the DHN model up to date –within the boundaries of available resources –by implementing an alert system that automatically collects new information published on the role of hormone signaling in dementia and enriches the model with the emerging knowledge. It is anticipated that, with the availability of more data, the resolution (i.e. specificity and sensitivity) of the model will increase so that new versions of the model will support translational scientists to make informed decisions.

Conclusions

The integrated hormone interaction model presented in this study can be beneficial in correlating the information of genes, proteins, signaling pathways and the clinical manifestation of dementia in the context of endocrine system. Such models have great potential to support the process of identifying new targets and novel biomarkers and help the pharmaceutical industry to increase the efficiency of their pipeline.

Additional files

Additional file 1: Analysis of dementia-related proteins for pathway enrichment. Results of GSEA pathway analysis on the list of dementia-related genes/proteins that were retrieved from the literature show a weak indication for presence of a subtle hormone signaling component. Description: Result table of GSEA pathway analysis on the list of literature-derived genes/proteins.

Additional file 2: Analysis of dementia-related proteins for GO biological processes enrichment. Results of GSEA GO (Biological Process) analysis again point to subtle hormone-dependent biological processes. Description: Result table of GSEA GO biological process analysis on the list of literature-derived genes/proteins.

Additional file 3: Module subnetworks of DHN. Module subnetworks - produced by cluster analysis of DHN - have been provided in a single XGMMML file, which can be loaded, viewed and navigated through the Cytoscape software. Description: Subnetworks of DHN representing modules enriched for edge attributes.

Additional file 4: Enrichment analysis results for each module subnetwork of DHN. Detailed results of gene set enrichment analysis

for proteins of four giant components (modules) using the category of GO Biological Process. Description: Result table of GSEA GO biological process analysis on each DHN modules.

Additional file 5: List of genomic neuroendocrine hormones and their corresponding receptors in DHN. The table lists the genomic hormones, their coding genes, their presence in the DHN model, and their corresponding receptor proteins in DHN. Description: Genomic hormones and their corresponding receptors have been retrieved from literature and manually curated.

Additional file 6: Annotations of DHN interactions to brain regions. Protein-protein interactions in DHN have been annotated to brain regions where they interact (1 represents an interaction and 0 represents no interaction). Description: Annotation of DHN protein interactions to brain regions supported by extra information.

Additional file 7: Putative AD biomarkers in the core DHN supported by gene expression data and pathway membership.

Additional file 8: General analysis of the drug-target space in the core DHN model. Proteins in the core DHN model have been annotated with all non-dementia drugs that target them and supporting evidence from the literature reporting positive (highlighted in green), negative (highlighted in red), and neutral (highlighted in grey) effects on cognition or memory or learning. Description: Systematic analysis of the drug-target space in the core DHN model for off-target effects on dementia.

Competing interests

Authors declare no competing interests.

Authors' contributions

EY conceived of the study, designed the methodology, performed analyses, and drafted the manuscript. MHA revised the results critically and supported the study. All authors read and approved the final manuscript.

Acknowledgements

Authors wish to thank Dr. Dieter Scheller and Dr. Jonathan Van Eyll from UCB Pharma for reviewing the manuscript.

Received: 5 April 2013 Accepted: 3 July 2013

Published: 26 July 2013

References

- Brooks DJ: **Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography.** *Mov Disord* 2009, **24**(Suppl 2):S742-S747.
- Vanmechelen E, Vanderstichele H, Hulstaert F, Andreasen N, Minthon L, Winbald B, Davidsson P, Blennow K: **Cerebrospinal fluid τ and β -amyloid (1-42) in dementia disorders.** *Mech Ageing Dev* 2001, **122**:2005-2011.
- Ross CA, Poirier MA: **Protein aggregation and neurodegenerative disease.** *Nat Med* 2004, **10**:S10-S17.
- Maji SK, Perrin MH, Sawaya MR, Jessberger S, Vadodaria K, Rissman RA, Singru PS, Nilsson KP, Simon R, Schubert D, Eisenberg D, Rivier J, Sawchenko P, Vale W, Riek R: **Functional amyloids as natural storage of peptide hormones in pituitary secretory granules.** *Science* 2009, **325**:328-332.
- Gibbs RB: **Estrogen therapy and cognition: a review of the cholinergic hypothesis.** *Endocr Rev* 2010, **31**:224-253.
- Artero S, Ancelin ML, Portet F, Dupuy A, Berr C, Dartigues JF, Tzourio C, Rouaud O, Poncet M, Pasquier F, Auriacombe S, Touchon J, Ritchie K: **Risk profiles for mild cognitive impairment and progression to dementia are gender specific.** *J Neurol Neurosurg Psychiatry* 2008, **79**:979-984.
- Ravaglia G, Forti P, Maioli F, Bastagli L, Montesi F, Pisacane N, Chiappelli M, Licastro F, Patterson C: **Endogenous sex hormones as risk factors for dementia in elderly men and women.** *J Gerontol A Biol Sci Med Sci* 2007, **62**:1035-1041.
- Jorm AF, Jolley D: **The incidence of dementia, a meta analysis.** *Neurology* 1998, **51**:728-733.
- Paganini-Hill A, Henderson V: **Estrogen replacement therapy and risk of Alzheimer disease.** *Arch Intern Med* 1996, **156**:2213-2217.

10. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R: **Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.** *Lancet* 1996, **348**:429–432.
11. Zandi P, Carlson M, Plassman B, Welsh-Bohmer K, Mayer L, Steffens D, Breitner J: **Hormone replacement therapy and incidence of Alzheimer disease in older women.** *JAMA-J Am Med Assoc* 2002, **288**:2123–2129.
12. Espeland M, Rapp S, Shumaker S, Brunner R, Manson J, Sherwin B, Hsia J, Margolis K, Hogan P, Wallace R, Dailey M, Freeman R, Hays J: **Conjugated equine estrogens and global cognitive function in postmenopausal women.** *JAMA-J Am Med Assoc* 2004, **291**:2959–2968.
13. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smolter S, Wactawski-Wende J: **Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The women's health initiative memory study: a randomized controlled trial.** *JAMA-J Am Med Assoc* 2003, **289**:2651–2662.
14. Ryan J, Carriere I, Scali J, Dartigues JF, Tzourio C, Poncet M, Ritchie K, Ancelin ML: **Characteristics of hormone therapy, cognitive function, and dementia.** *Neurology* 2009, **73**:1729–1737.
15. Lieb W, Beiser AS, Vasan RS, Tan ZS, Au R, Harris TB, Roubenoff R, Auerbach S, DeCarli C, Wolf PA, Seshadri S: **Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging.** *JAMA-J Am Med Assoc* 2009, **302**:2565–2572.
16. Tezapsidis N, Johnston JM, Smith MA, Ashford JW, Casadesus G, Robakis NK, Wolozin B, Perry G, Zhou X, Greco SJ, Sarkar S: **Leptin: a novel therapeutic strategy for Alzheimer's disease.** *J Alzheimers Dis* 2009, **16**:731–740.
17. Maurizi CP: **Loss of intraventricular fluid melatonin can explain the neuropathology of Alzheimer's disease.** *Med Hypotheses* 1997, **49**:153–158.
18. Liu RY, Zhou JN, van Heerikhuizen J, Hofman MA, Swaab DF: **Decreased melatonin levels in post-mortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype.** *J Clin Endocrinol Metab* 1999, **84**:323–327.
19. Mishima K, Tozawa T, Satoh K, Matsumoto Y, Hishikawa Y, Okawa M: **Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking.** *Biol Psychiatry* 1999, **45**:417–421.
20. Atsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B, Herbert D, Cruz-Sanchez F, Chyan YJ, Smith MA, Perry G, Shoji M, Abe K, Leone A, Grundke-Ikbal I, Wilson GA, Ghiso J, Williams C, Refolo LM, Pappolla MA, Chain DG, Neria E: **Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease.** *J Neurochem* 2003, **85**:1101–1108.
21. Breteler MM, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A, Jorm AF, Kokmen E, Kondo K, Mortimer JA, Rocca WA, Shalat SL, Soininen H, Hofman A: **Medical history and the risk of Alzheimer's disease: a collaborative re-analysis of case-control studies.** *Int J Epidemiol* 1991, **20**(Suppl 2):S36–S42.
22. Ganguli M, Burmeister LA, Seaberg EC, Belle S, DeKosky ST: **Association between dementia and elevated TSH: a community-based study.** *Biol Psychiatry* 1996, **40**:714–725.
23. Fu AL, Zhou CY, Chen X: **Thyroid hormone prevents cognitive deficit in a mouse model of Alzheimer's disease.** *Neuropharmacology* 2010, **58**:722–729.
24. May C, Rapoport SI, Tomai TP, Chrousos GP, Gold PW: **Cerebral spinal fluid concentrations of corticotropin-releasing hormone (CRH) and corticotropin (ACTH) are reduced in patients with Alzheimer's disease.** *Neurology* 1987, **37**:535–538.
25. Pomara N, Singh RR, Deptula D, LeWitt PA, Bissette G, Stanley M, Nemeroff CB: **CSF corticotropin-releasing factor (CRH) in Alzheimer's disease. Its relationship to severity of dementia and monoamine metabolites.** *Biol Psychiatr* 1989, **26**:500–504.
26. Aleman A, Verhaar HJ, de Haan EHF, De Vries WR, Samson MM, Drent ML, Van der Veen EA, Koppeschaar HP: **Insulin-like growth factor-I and cognitive function in healthy older men.** *J Clin Endocrinol Metab* 1999, **84**:471–475.
27. Rollero A, Murialdo G, Fonzi S, Garrone S, Gianelli MV, Gazzero E, Barreca A, Polleri A: **Relationship between cognitive function, growth hormone and insulin-like growth factor I plasma levels in aged subjects.** *Neuropsychobiology* 1998, **23**:45–55.
28. Lackey BR, Gray SL, Henricks DM: **Actions and interactions of the IGF system in Alzheimer's Disease: review and hypotheses.** *Growth Horm IGF Res* 2000, **10**:1–13.
29. Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS: **Growth hormone releasing hormone improves the cognition of healthy older adults.** *Neurobiol Aging* 2006, **27**:318–323.
30. Chen DY, Stern SA, Garcia-Osta A, Saunier-Rebori B, Pollonini G, Bambah-Mukku D, Blitzer RD, Alberini CM: **A critical role for IGF-II in memory consolidation and enhancement.** *Nature* 2011, **469**:491–497.
31. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr: **Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype.** *Neurology* 1998, **50**:164–168.
32. Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, Purganan K, Wait C, Petrova A, Latendresse S, Watson GS, Newcomer JW, Schellenberg GD, Krohn AJ: **Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype.** *Psychoneuroendocrinol* 2003, **28**:809–822.
33. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C: **Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signaling.** *Neurobiol Aging* 2010, **31**:224–243.
34. Baker LD, Cross DJ, Minoshima S, Belongia D, Stennis Watson G, Craft S: **Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes.** *Arch Neurol* 2011, **68**:51–57.
35. Sims-Robinson C, Kim B, Rosko A, Feldman EL: **How does diabetes accelerate Alzheimer disease pathology?** *Nat Rev Neurol* 2010, **6**:551–559.
36. Ott A, Stolk RP, van Harskamp F, Grobbee DE, Breteler MM: **Diabetes mellitus and the risk of dementia: the Rotterdam study.** *Neurology* 1999, **53**:1937–1942.
37. de la Monte SM, Wands JR: **Alzheimer's disease is type 3 diabetes-evidence reviewed.** *J Diabetes Sci Technol* 2008, **2**:1101–1113.
38. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB: **Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?** *Brit J Clin Pharmacol* 2011, **71**:365–376.
39. Saleh N, Moutereau S, Durr A, Krystkowiak P, Azulay JP, Tranchant C, Broussolle E, Morin F, Bachoud-Lévi AC, Maison P: **Neuroendocrine disturbances in huntington's disease.** *PLoS One* 2009, **3**:e4962.
40. Ogishima S, Mizuno S, Kikuchi M, Miyashita A, Kuwano R, Tanaka H, Nakaya J: **A map of Alzheimer's disease-signaling pathways: a hope for drug target discovery.** *Clin Pharmacol Ther* 2013, **93**:399–401.
41. Hanisch D, Fundel K, Mevissen HT, Zimmer R, Fluck J: **ProMiner: rule based protein and gene entity recognition.** *BMC Bioinformatics* 2005, **6**(Suppl 1):S14.
42. Friedrich CM, Dach H, Gattermayer T, Engelbrecht G, Benkner S, Hofmann-Apitius M: **@neuLink: a service-oriented application for biomedical knowledge discovery.** In *Proceedings of the HealthGrid:2-4 June 2008*. Edited by Tony S, Silverstein JC, Joel S, Yannick L, Mary K, Ian F, Vincent B, Robert Beck J. Chicago: IOS Press Amsterdam; 2008:165–172.
43. Potapov A, Liebich I, Dönitz J, Schwarzer K, Sasse N, Schoeps T, Crass T, Wingender E: **EndoNet: an information resource about endocrine networks.** *Nucleic Acids Res* 2006, **34**:D540–D545.
44. Ramón AJG, Baldo O: **Integration and Prediction of PPI Using Multiple Resources from Public Databases.** *J Proteomics Bioinform* 2008, **1**:166–187.
45. Killcoyne S, Carter GW, Smith J, Boyle J: **Cytoscape: a community-based framework for network modeling.** *Methods Mol Biol* 2009, **563**:219–239.
46. Bastian M, Heymann S, Jacomy M: **Gephi: an open source software for exploring and manipulating networks.** In *Proceedings of the Third International Conference on Weblogs and Social Media*. Edited by Adar E, Hurst M, Finin T, Glance N, Nicolov N, Tseng B. San Jose, California: AAAI Press; 2009:361–362.
47. Su G, Kuchinsky A, Morris JH, States DJ, Meng F: **Gly: community structure analysis of biological networks.** *Bioinformatics* 2010, **26**:3135–3137.
48. Nishimura D: **BioCarta.** *Biotech Softw Internet Rep* 2011, **2**:117–120.
49. Frühbeck G: **Intracellular signalling pathways activated by leptin.** *Biochem J* 2006, **393**:7–20.
50. Moeller LC, Cao X, Dumitrescu AM, Seo H, Refetoff S: **Thyroid hormone mediated changes in gene expression can be initiated by cytosolic action of the thyroid hormone receptor β through the phosphatidylinositol 3-kinase pathway.** *Nucl Recept Signal* 2006, **4**:e020. *QIAGEN Pathway Navigator*. <http://www.qiagen.com/products/genes%20and%20pathways/Pathway%20Details.aspx?pwid=124>.

52. Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI: **Molecular pharmacology, regulation and function of mammalian melatonin receptors.** *Front Biosci* 2003, **8**:d1093–d1108.
53. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP: **Molecular signatures database (MSigDB) 3.0.** *Bioinformatics* 2011, **27**:1739–1740.
54. Huang DW, Sherman BT, Lempicki RA: **Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources.** *Nat Protoc* 2009, **4**:44–57.
55. *The Mouse Genome Informatics Database.* www.informatics.jax.org/.
56. Younesi E, Toldo L, Müller B, Friedrich CM, Novac N, Scheer A, Hofmann-Apitius M, Fluck J: **Mining biomarker information in biomedical literature.** *BMC Med Inform Decis* 2012, **12**:148.
57. *The Kyoto Encyclopedia of Genes and Genomes Database.* www.genome.jp/kegg/.
58. *The Genetic Association Database.* geneticassociationdb.nih.gov.
59. *The Tissue Distribution Database.* genome.dkfz-heidelberg.de/menu/tissue_db/.
60. *The DrugBank Database.* www.drugbank.ca/.
61. Barabasi AL, Oltvai ZN: **Network biology: understanding the cell's functional organization.** *Nat Rev Genet* 2004, **5**:101–113.
62. Bossi A, Lehner B: **Tissue specificity and the human protein interaction network.** *Mol Syst Biol* 2009, **5**:260.
63. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW: **The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in cerebral cortex of patients with Alzheimer's disease.** *Cereb Cortex* 1991, **1**:103–116.
64. Davis JD, Podolanczuk A, Donahue JE, Stopa E, Hennessey JV, Luo LG, Lim YP, Stern RA: **Thyroid hormone levels in the prefrontal cortex of post-mortem brains of Alzheimer's disease patients.** *Curr Aging Sci* 2008, **1**:175.
65. Dai J, Buijs R, Swaab D: **Glucocorticoid hormone (cortisol) affects axonal transport in human cortex neurons but shows resistance in Alzheimer's disease.** *Br J Pharmacol* 2004, **143**:606–610.
66. Souza EB, Whitehouse PJ, Price DL, Vale WW: **Abnormalities in Corticotropin-releasing Hormone (CRH) in Alzheimer's disease and other human disorders.** *Ann N Y Acad Sci* 1987, **512**:237–247.
67. Ishunina TA, Kamphorst W, Swaab DF: **Metabolic alterations in the hypothalamus and basal forebrain in vascular dementia.** *J Neuropathol Exp Neurol* 2004, **63**:1243–1254.
68. Murialdo G, Zerbi F, Filippi U, Tosca P, Fonzi S, Di Paolo E, Costelli P, Porro S, Polleri A, Savoldi F: **Cholinergic modulation of growth hormone-releasing hormone effects on growth hormone secretion in dementia.** *Neuropsychobiology* 2008, **24**:129–134.
69. Keenan PA, Ezzat WH, Ginsburg K, Moore GJ: **Prefrontal cortex as the site of estrogen's effect on cognition.** *Psychoneuroendocrinology* 2001, **26**:577–590.
70. Watson GS, Bernhardt T, Reger MA, Cholerton BA, Baker D, Peskin ER, Asthana S, Plymate SR, Frölich L, Craft S: **Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease.** *Neurobiol Aging* 2006, **27**:38–41.
71. Arwert LI, Veltman DJ, Deijen JB, van Dam PS, Drent ML: **Effects of growth hormone substitution therapy on cognitive functioning in growth hormone deficient patients: a functional MRI study.** *Neuroendocrinology* 2006, **83**:12–19.
72. Zhu DF, Wang ZX, Zhang DR, Pan ZL, He S, Hu XP, Chen XC, Zhou JN: **fMRI revealed neural substrate for reversible working memory dysfunction in subclinical hypothyroidism.** *Brain* 2006, **129**:2923–2930.
73. Liang WS, Duncley T, Beach TG, Grover A, Mastroeni D, Ramsey K, Caselli RJ, Kukull WA, McKeel D, Morris JC, Hulette CM, Schmechel D, Reiman EM, Rogers J, Stephan DA: **Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set.** *Physiol Genomics* 2008, **33**:240–256.
74. Liang D, Han G, Feng X, Sun J, Duan Y, Lei H: **Concerted perturbation observed in a hub network in Alzheimer's disease.** *PLoS One* 2012, **7**:e40498.
75. MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK: **Identifying off-target effects and hidden phenotypes of drugs in human cells.** *Nat Chem Biol* 2006, **2**:329–337.
76. Singh M, Sétáló G, Guan X, Warren M, Toran-Allerand CD: **Estrogen-induced activation of mitogen-activated protein kinase in cerebral cortical explants: convergence of estrogen and neurotrophin signaling pathways.** *J Neurosci* 1999, **19**:1179–1188.
77. Craft S, Asthana S, Schellenberg G, Cherrier M, Baker LD, Newcomer J, Plymate S, Latendresse S, Petrova A, Raskind M, Peskind E, Lofgreen C, Grimwood K: **Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender.** *Neuroendocrinology* 1999, **70**:146–152.
78. Cardona-Gomez P, Perez M, Avila J, Garcia-Segura LM, Wandosell F: **Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and β -catenin in the hippocampus.** *Mol Cell Neurosci* 2004, **25**:363–373.
79. Cuadrado A, Garcia-Fernandez LF, Imai T, Okano H, Munoz A: **Regulation of tau RNA maturation by thyroid hormone is mediated by the neural RNA-binding protein Musashi-1.** *Mol Cell Neurosci* 2002, **20**:198–210.
80. Wang JZ, Wang ZF: **Role of melatonin in Alzheimer-like neurodegeneration.** *Acta Pharmacol Sin* 2006, **27**:41–49.
81. Rissman RA, Lee KF, Vale W, Sawchenko PE: **Corticotropin-releasing factor receptors differentially regulate stress-induced τ phosphorylation.** *J Neurosci* 2007, **27**:6552–6562.
82. Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, Kanba S, Kiyohara Y: **Glucose tolerance status and risk of dementia in the community: the Hisayama study.** *Neurology* 2011, **77**:1126–1134.
83. Hsu CC, Wahlgvist ML, Lee MS, Tsai HN: **Incidence of Dementia is Increased in Type 2 Diabetes and Reduced by the Use of Sulfonylureas and Metformin.** *J Alzheimers Dis* 2011, **24**:485–493.
84. Xu W, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L: **Mid- and Late-life diabetes in relation to the risk of dementia: a population-based twin study.** *Diabetes* 2009, **58**:71–77.
85. Yaffe K, Falvey C, Hamilton N, Schwartz AV, Simonsick EM, Satterfield S, Cauley JA, Rosano C, Launer LJ, Strotmeyer ES, Harris TB: **Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia.** *Arch Neurol* 2012, **9**:1170–1175.
86. Cammarota M, Bevilacqua LRM, Ardenghi P, Paratcha G, Levi de Stein M, Izquierdo I, Medina JH: **Learning-associated activation of nuclear MAPK, CREB and Elk-1, along with Fos production, in the rat hippocampus after a one-trial avoidance learning: abolition by NMDA receptor blockade.** *Mol Brain Res* 2000, **76**:36–46.
87. Zhao WQ, Alkon DL: **Role of insulin and insulin receptor in learning and memory.** *Mol Cell Endocrinol* 2001, **177**:125–134.
88. Zhao WQ, Chen H, Quon MJ, Alkon DL: **Insulin and the insulin receptor in experimental models of learning and memory.** *Eur J Pharmacol* 2004, **490**:71–81.
89. Jucker M: **The benefits and limitations of animal models for translational research in neurodegenerative diseases.** *Nat Med* 2010, **16**:1210–1214.
90. Hölscher C: *Neuronal mechanisms of memory formation: concepts of long term potentiation and beyond.* Cambridge: Cambridge University Press; 2001.
91. Lynch MA: **Long-term potentiation and memory.** *Physiol Rev* 2004, **84**:87–136.
92. Buxbaum JD, Cullen EI, Friedhoff LT: **Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients.** *Front Biosci* 2002, **7**:a50–a59.
93. Banks WA: **Brain meets body: the blood-brain barrier as an endocrine interface.** *Endocrinology* 2012, **9**:4111–4119.

doi:10.1186/1479-5876-11-177

Cite this article as: Younesi and Hofmann-Apitius: A network model of genomic hormone interactions underlying dementia and its translational validation through serendipitous off-target effect. *Journal of Translational Medicine* 2013 **11**:177.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

